Sensus Healthcare, Inc.
Moat Score — Sensus Healthcare, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Sensus's SRT-100 family carries FDA clearances and device-specific IP for superficial radiation therapy, but the underlying SRT modality itself is not uniquely Sensus's to practice. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small medical device maker with a 955-unit installed base, Sensus has no manufacturing or distribution cost advantage over larger radiation oncology equipment makers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | The Fair Deal Agreement revenue-share model and premium-tier SRT-100 Vision/SRT-100+ systems suggest some ability to price for differentiated clinical value, tempered by competition from established linear-accelerator-based alternatives. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Each SRT-100 system functions independently at the practice that owns or leases it, with no network effect between Sensus's installed units. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a dermatology or radiation oncology practice has trained staff and built a clinical workflow around an SRT-100 system, switching to a different treatment modality involves real retraining and capital-equipment costs, giving Sensus modest retention. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | A 955-unit global installed base is small relative to the broader radiation oncology equipment market, so Sensus's current scale does not meaningfully deter new entrants into the superficial radiation therapy niche. |